GSK readies "bubble boy" drug as big pharma bets on gene therapy
April 27, 2015 at 10:04 AM EDT
LONDON, April 27 (Reuters) - GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes.